GnRH antagonists have several clinical applications in prostate cancer, regulation of ovulation induction in females, breast cancer, male contraception and others. Antagonists differ from natural GnRH decapeptide in having five or more amino acid substitutions, whereas most of the antagonists are available as subcutaneous (SC) formula for injection some are formulated as a depot formulation for sustained release (e.g., Cetrorelix, Degarelix). Systemic delivery of cetrorelix acetate by intratracheal route can be achieved using dry powder for inhalation of the adhesive mixture when the powder deposition reaches stage four. The oral route for systemic delivery of peptide without its degradation can be achieved using gastrointestinal permeation enhancement technology GIPET® provided by acyline.
Keywords: Cetrorelix, extrusion, GnHR antagonist, microparticles, peptide, subcutaneous, testesteron.
Targeting Heat Shock Proteins in Prostate Cancer
Current Medicinal Chemistry Persistent P21Cip1 Induction Mediates G1 Cell Cycle Arrest by Methylseleninic Acid in DU145 Prostate Cancer Cells
Current Cancer Drug Targets Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotides: Proof of Principle, In Vitro and In Vivo Activities, and Mechanisms
Current Cancer Drug Targets Adrenomedullin: A Tumor Progression Factor via Angiogenic Control
Current Cancer Drug Targets Changes in and Impact of the Death Review Process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
Reviews on Recent Clinical Trials SPARC in Tumor Pathophysiology and as a Potential Therapeutic Target
Current Pharmaceutical Design Zinc Tetrafluoroborate Catalyzed Synthesis, Molecular Docking and Cytotoxicity of Pyrrolidinyl Aminophosphonates
Letters in Drug Design & Discovery Current State of ERG as Biomarker in Prostatic Adenocarcinoma
Current Cancer Drug Targets Molecular Foundations for Personalized Therapy in Prostate Cancer
Current Drug Targets Molecular Tests for the Choice of Cancer Therapy
Current Pharmaceutical Design Genetics, Structure, Function, Mode of Actions and Role in Cancer Development of CYP17
Anti-Cancer Agents in Medicinal Chemistry Optimal Sequencing of New Drugs in Metastatic Castration-Resistant Prostate Cancer: Dream or Reality?
Current Drug Targets Estrone (E1) Based Esters as Potential Inhibitors of Type 3 17β- hydroxysteroid Dehydrogenase (17β-HSD3) in the Treatment of Hormone-Dependent Prostate Cancer
Letters in Drug Design & Discovery Nuclear Targeting and Retention of Anthracycline Antitumor Drugs in Sensitive and Resistant Tumor Cells
Current Medicinal Chemistry PET Imaging with [<sup>68</sup>Ga]NOTA-RGD for Prostate Cancer: A Comparative Study with [<sup>18</sup>F]Fluorodeoxyglucose and [<sup>18</sup>F]Fluoroethylcholine
Current Cancer Drug Targets Prostate-Apoptosis-Response-Gene-4: Biological Properties and their Potential Therapeutic Exploitation in Hematological Malignancies
Letters in Drug Design & Discovery Heparin Affin Regulatory Peptide: A New Target for Tumour Therapy?
Current Cancer Drug Targets The Estrogenic Burden on Vascular Risk in Male-to-Female Transsexuals
Current Pharmaceutical Design Cytotoxic Compounds in the Treatment of Castration-Resistant Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Carotenoids and Prostate Cancer Risk
Mini-Reviews in Medicinal Chemistry